Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3885125 in Dyslipidemia and NAFLD
NCT06007651Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY-3885125 in dyslipidemia and non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration at 36 weeks. Started Aug 2023; status: terminated.
02
Drugs
LY-3885125
03
Conditions
dyslipidemianon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06007651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007651.